The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation

Xiaoman Liu; Mengying Pi; Mukai Chen; Shirong Cai; Yulong He; Ke-Jing Tang; Xinhua Zhang; Yanzhe Xia

doi:10.1093/oncolo/oyaf176

The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation

Oncologist. 2025 Jul 2:oyaf176. doi: 10.1093/oncolo/oyaf176. Online ahead of print.

Authors

Xiaoman Liu¹, Mengying Pi^{1

2}, Mukai Chen³, Shirong Cai⁴, Yulong He⁴, Ke-Jing Tang^{1

5}, Xinhua Zhang⁴, Yanzhe Xia¹

Affiliations

¹ Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
² Department of Pharmacy, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
³ Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
⁴ Center for Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
⁵ Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

PMID: 40592735
DOI: 10.1093/oncolo/oyaf176

Abstract

Background: Skin rash is one of the most common imatinib-associated adverse events in patients with gastrointestinal stromal tumors (GISTs), potentially compromising treatment adherence and therapeutic efficacy. This study presents a personalized desensitization management of imatinib-associated severe rash with therapeutic drug monitoring (TDM) and pharmacogenetic investigation.

Patients and methods: Among 712 patients with GIST receiving imatinib, 54 patients (7.6%) developed severe skin rash (grade 3: 37 patients, recurrent grade 2: 17 patients) and underwent personalized desensitization treatment. This approach involved a temporary cessation of imatinib and initiation of systemic steroids, followed by reintroduction of imatinib with TDM-assisted gradual dose escalation, while steroids were tapered until discontinuation. Pharmacogenetic analysis was conducted to explore potential genetic susceptibility.

Results: Following desensitization therapy for severe rash, the majority of patients (92.6%) successfully resumed imatinib treatment at personalized maintenance doses. Grade 3 rash occurred earlier than recurrent grade 2 rash before desensitization therapy (P = 0.004) and was associated with lower final maintenance doses of imatinib after desensitization (P = 0.010). The final imatinib trough concentrations post-desensitization were significantly lower than those at rash onset (P < 0.001). Pharmacogenetic analysis identified IL-6R rs4129267 as significantly associated with imatinib-associated severe skin rash (odds ratio 1.966, 95% CI, 1.143-3.380, P = 0.015).

Conclusion: Personalized desensitization therapy assisted by TDM could effectively manage imatinib-associated severe skin rash. The early onset of grade 3 rash underscored the importance of vigilant monitoring during the initial phase of imatinib treatment. Genetic variant in IL-6R may be involved in rash pathogenesis.

Keywords: Imatinib; desensitization; gastrointestinal stromal tumors; pharmacogenetics; skin rash; therapeutic drug monitoring.